In vivo disposition of dermorphin analog (DALDA) in nonpregnant and pregnant sheep
- PMID: 9435161
In vivo disposition of dermorphin analog (DALDA) in nonpregnant and pregnant sheep
Abstract
Although synthetic opioid peptide analogs have been used extensively to study the functional roles of opioid receptors, little is known about their in vivo disposition. Our goal was to develop novel opioid drugs with limited transfer across the placenta. DALDA (Tyr-D-Arg-Phe-Lys-NH2) is a potent and highly selective mu agonist that is quite polar because of its 3+ charge at physiological pH. It can therefore be expected that the distribution of DALDA across the placenta would be highly restricted. In this study, we determined the pharmacokinetics and placental transfer of DALDA after systemic administration in sheep. DALDA was infused intravenously to four nonpregnant and four pregnant sheep at a dose of 0.6 mg/kg/hr for 4 hr. Steady state plasma levels of DALDA were 5436 +/- 464 ng/ml in nonpregnant sheep and 5214 +/- 661 ng/ml in pregnant sheep. A one-compartment open model provided an excellent fit for nonpregnant and pregnant plasma data. The apparent volume of distribution was estimated to be 45.6 +/- 4.4 and 59.2 +/- 7.9 ml/kg in nonpregnant and pregnant animals, respectively. There was no difference in the elimination half-life of DALDA in nonpregnant (1.4 +/- 0.1 hr) and pregnant (1.7 +/- 0.2 hr) animals, and clearance was also similar in nonpregnant (23.1 +/- 1.7 ml/kg/hr) and pregnant (23.7 +/- 1.3 ml/kg/hr) animals. These data suggest that the distribution of DALDA is restricted to plasma volume and that its disposition is not altered in pregnancy. DALDA was not detected in any of the fetal plasma samples (< 50 ng/ml), indicating that fetal plasma concentration is < 1% of maternal concentration. The highly restricted placental distribution of DALDA suggests that it may be a promising opioid drug for obstetrical use.
Similar articles
-
Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.J Pharmacol Exp Ther. 2003 Aug;306(2):430-6. doi: 10.1124/jpet.103.049742. Epub 2003 Mar 27. J Pharmacol Exp Ther. 2003. PMID: 12663687
-
In vivo pharmacokinetics of selective mu-opioid peptide agonists.J Pharmacol Exp Ther. 2001 Jul;298(1):57-61. J Pharmacol Exp Ther. 2001. PMID: 11408525
-
Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1] DALDA.J Pharmacol Exp Ther. 2001 Apr;297(1):364-71. J Pharmacol Exp Ther. 2001. PMID: 11259564
-
New approaches for drug and kinetic analysis in the maternal-fetal unit.NIDA Res Monogr. 1995;154:175-202. NIDA Res Monogr. 1995. PMID: 8606744 Review.
-
Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery.J Pharmacol Exp Ther. 1994 Feb;268(2):791-6. J Pharmacol Exp Ther. 1994. PMID: 8113991
Cited by
-
The placenta as a target of opioid drugs†.Biol Reprod. 2022 Apr 26;106(4):676-686. doi: 10.1093/biolre/ioac003. Biol Reprod. 2022. PMID: 35024817 Free PMC article. Review.
-
Peripherally Acting μ-Opioid Receptor Agonists Attenuate Ongoing Pain-associated Behavior and Spontaneous Neuronal Activity after Nerve Injury in Rats.Anesthesiology. 2018 Jun;128(6):1220-1236. doi: 10.1097/ALN.0000000000002191. Anesthesiology. 2018. PMID: 29601322 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials